Literature DB >> 34193457

How long does covid-19 immunity last?

Chris Baraniuk1.   

Abstract

Entities:  

Year:  2021        PMID： 34193457     DOI： 10.1136/bmj.n1605

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  13 in total

1.  BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages.

Authors:  Bernd Jahrsdörfer; Matthias Proffen; Judith Scholz; Janina Hägele; Carolin Ludwig; Christiane Vieweg; Aline Grempels; Dorit Fabricius; Ramin Lotfi; Sixten Körper; Guido Adler; Hubert Schrezenmeier
Journal:  Front Immunol       Date:  2022-06-20       Impact factor: 8.786

2.  Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy.

Authors:  Giovanni Corrao; Matteo Franchi; Danilo Cereda; Francesco Bortolan; Alberto Zoli; Olivia Leoni; Catia Rosanna Borriello; Giulia Petra Della Valle; Marcello Tirani; Giovanni Pavesi; Antonio Barone; Michele Ercolanoni; Jose Jara; Massimo Galli; Guido Bertolaso; Giuseppe Mancia
Journal:  Lancet Infect Dis       Date:  2022-01-28       Impact factor: 71.421

3.  COVID-19 Recovery Patterns Across Alpha (B.1.1.7) and Delta (B.1.617.2) Variants of SARS-CoV-2.

Authors:  Nitya Kumar; Suha Quadri; Abdulla Ismaeel AlAwadhi; Manaf AlQahtani
Journal:  Front Immunol       Date:  2022-02-14       Impact factor: 7.561

Review 4.  Eight Good Reasons for Careful Monitoring and Evaluation of the Vaccine Campaign against COVID-19: Lessons Learned through the Lombardy Experience for Dealing with Next Challenges.

Authors:  Giovanni Corrao; Guido Bertolaso; Giovanni Pavesi; Letizia Moratti
Journal:  Int J Environ Res Public Health       Date:  2022-01-19       Impact factor: 3.390

5.  T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern.

Authors:  Hila Cohen; Shahar Rotem; Uri Elia; Gal Bilinsky; Itzchak Levy; Theodor Chitlaru; Erez Bar-Haim
Journal:  Viruses       Date:  2022-02-08       Impact factor: 5.048

6.  Social network-based ethical analysis of COVID-19 vaccine supply policy in three Central Asian countries.

Authors:  Timur Aripov; Daniel Wikler; Damin Asadov; Zhangir Tulekov; Totugul Murzabekova; Kerim M Munir
Journal:  BMC Med Ethics       Date:  2022-03-09       Impact factor: 2.652

7.  Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays.

Authors:  Beomki Lee; Jae-Hoon Ko; Jiho Park; Hee-Won Moon; Jin Yang Baek; Sunhee Jung; Hee-Young Lim; Kyung-Chang Kim; Kyungmin Huh; Sun Young Cho; Cheol-In Kang; Doo Ryeon Chung; Hee Jae Huh; Chi Ryang Chung; Yae-Jean Kim; Eun-Jeong Joo; Eun-Suk Kang; Kyong Ran Peck
Journal:  Front Cell Infect Microbiol       Date:  2022-04-14       Impact factor: 6.073

8.  Social network-based ethical analysis of COVID-19 vaccine supply policy in three Central Asian countries.

Authors:  Timur Aripov; Daniel Wikler; Damin Asadov; Zhangir Tulekov; Totugul Murzabekova; Kerim Munir
Journal:  Res Sq       Date:  2021-07-26

9.  Seven-Month Analysis of Five SARS-CoV-2 Antibody Assay Results after ChAdOx1 nCoV-19 Vaccination: Significant Decrease in SARS-CoV-2 Antibody Titer.

Authors:  Seri Jeong; Nuri Lee; Su-Kyung Lee; Eun-Jung Cho; Jungwon Hyun; Min-Jeong Park; Wonkeun Song; Eun-Ju Jung; Heungjeong Woo; Yu-Bin Seo; Jin-Ju Park; Hyun-Soo Kim
Journal:  Diagnostics (Basel)       Date:  2021-12-30

10.  Equitable access to COVID-19 vaccines makes a life-saving difference to all countries.

Authors:  Yang Ye; Qingpeng Zhang; Xuan Wei; Zhidong Cao; Hsiang-Yu Yuan; Daniel Dajun Zeng
Journal:  Nat Hum Behav       Date:  2022-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.